tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Shihab FS et al. | Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. | 2008 | Transplantation | pmid:18475181 |
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Peterson LB et al. | A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. | 1998 | Transplantation | pmid:9448137 |
| Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
| Pirsch JD | Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. | 1999 | Transplantation | pmid:10551653 |
| Zoppo A et al. | Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. | 1999 | Transplantation | pmid:10551656 |
| Abbott KC et al. | New-onset gout after kidney transplantation: incidence, risk factors and implications. | 2005 | Transplantation | pmid:16340779 |
| Mañez R et al. | Fluconazole therapy in transplant recipients receiving FK506. | 1994 | Transplantation | pmid:7515201 |
| Hirose R et al. | Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. | 2000 | Transplantation | pmid:10670644 |
| Hirano Y et al. | Morphological and functional changes of islets of Langerhans in FK506-treated rats. | 1992 | Transplantation | pmid:1373536 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Sindhi R et al. | Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. | 2001 | Transplantation | pmid:11571449 |
| Jain A et al. | Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. | 2000 | Transplantation | pmid:11087149 |
| Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
| Koomans HA and Ligtenberg G | Mechanisms and consequences of arterial hypertension after renal transplantation. | 2001 | Transplantation | pmid:11585243 |
| Trimarchi HM et al. | FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. | 1999 | Transplantation | pmid:10071024 |
| Diem HV et al. | Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. | 2003 | Transplantation | pmid:12777858 |
| Luan FL et al. | Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. | 2002 | Transplantation | pmid:12042641 |
| Smets F et al. | Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. | 2002 | Transplantation | pmid:12042647 |
| Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
| Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
| Kiuchi T | CNIs: immediate benefits but storing problems for the future? | 2008 | Transplantation | pmid:18946338 |
| Andoh TF et al. | Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. | 1994 | Transplantation | pmid:7509514 |
| Hadley S et al. | Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. | 1995 | Transplantation | pmid:7535482 |
| Alessiani M et al. | Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. | 1996 | Transplantation | pmid:8830816 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Furlan V et al. | Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. | 1995 | Transplantation | pmid:7537398 |
| Akst LM et al. | Induction of tolerance in a rat model of laryngeal transplantation. | 2003 | Transplantation | pmid:14688529 |
| Pacifico L et al. | Tacrolimus and food allergy. | 2003 | Transplantation | pmid:14688538 |
| Koch R et al. | Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. | 2003 | Transplantation | pmid:12973123 |
| Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. | 1999 | Transplantation | pmid:10030287 |
| Paty BW et al. | Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. | 2002 | Transplantation | pmid:11884930 |
| Dell'Antonio G and Randhawa PS | "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. | 1999 | Transplantation | pmid:10030300 |
| Vyas S et al. | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. | 1999 | Transplantation | pmid:10030303 |
| Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
| Ueda M et al. | A proposal of FK506 optimal dosing in living related liver transplantations. | 1995 | Transplantation | pmid:7544035 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| Paolillo JA et al. | Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. | 2001 | Transplantation | pmid:11213069 |
| Molmenti EP et al. | Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. | 2001 | Transplantation | pmid:11213072 |
| Pascual J et al. | Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. | 2010 | Transplantation | pmid:20335831 |
| Sahara H et al. | Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. | 2010 | Transplantation | pmid:21076382 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
| Vincenti F et al. | One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8669100 |
| Lauzurica R et al. | Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. | 2002 | Transplantation | pmid:11923710 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |
| Krämer BK et al. | Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. | 2012 | Transplantation | pmid:22858806 |
| Mayer AD et al. | Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. | 1997 | Transplantation | pmid:9275110 |